查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1828121

2025年血液学和肿瘤学检测全球市场报告

Hemato Oncology Testing Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，血液学和肿瘤学检测市场快速扩张，规模从2024年的35亿美元成长至2025年的39.3亿美元，复合年增长率达12.5%。预测期内的成长归因于癌症发生率的上升、意识提升的提高和筛检项目的推进、医疗保健支出的增加、个人化医疗的普及以及血液病患病率的上升。

预计未来几年血液学和肿瘤学检测市场将快速成长，到2029年将达到67.6亿美元，年复合成长率（CAGR）为14.5%。预测期内的增长可归因于个人化医疗趋势、人工智慧的整合、人口老化、基因组学研究的进步以及对早期癌症检测需求的不断增长。预测期内的主要趋势包括基因组学检测的技术进步、用于非侵入性检测的液态切片、行业合作与伙伴关係、监管格局和标准化以及技术进步。

血液肿瘤学检查包括用于识别血液疾病和血癌症状的诊断程序。这些检查在诊断贫血、感染疾病、血友病、血液凝固障碍和白血病等疾病方面发挥重要作用。

与血液学和肿瘤学检测相关的主要产品和服务包括检测试剂套件、试剂及相关服务。检测试剂套件和试剂包括用于分析特定物质的仪器和化学品。检测程序涵盖多种癌症类型，包括白血病、淋巴瘤、多发性骨髓瘤等。这些检测采用的技术包括聚合酵素链锁反应(PCR)、免疫组织化学 (IHC)、新一代定序 (NGS) 和其他先进技术。血液学和肿瘤学检测的最终用户包括医院、学术研究机构和其他医疗保健组织。

2025年春季美国关税的突然上调及其引发的贸易摩擦对医疗设备行业产生了重大影响，尤其对用于诊断影像设备的进口零件、手术用不銹钢和一次性塑胶製品产生了重大影响。由于医院和诊所抵制涨价，製造商面临利润压力。监管挑战使情况更加复杂，因为由于关税而更换供应商通常需要重新认证医疗设备，导致市场进入延迟。为此，企业正在透过双重采购关键零件、增加标准化产品的国内生产以及加快寻找更具成本效益的材料来降低风险。

本研究报告是商业研究公司 (The Business Research Company) 新报告系列的一部分，该系列提供血液肿瘤检测市场统计数据，例如全球市场规模、区域份额、血液肿瘤检测市场份额的竞争对手、详细的血液肿瘤检测细分市场、市场趋势以及血液肿瘤检测行业的商机，为您提供在血液肿瘤检测行业取得成功所需的数据。本血液肿瘤检测市场研究报告全面概​​述了您所需的一切，并详细分析了该行业的现状和未来前景。

未来五年的预测成长率为14.5%，较我们先前对该市场的预测略有下降0.1%。这一下降主要源自于美国与其他国家之间关税的影响。这种影响可能会直接影响美国，导致来自印度和爱尔兰等主要地区的流式细胞技术抗体和微量残存疾病检测套件的供应链中断，从而导致白血病诊断延迟和血液病理实验室成本增加。由于互惠关税以及贸易紧张局势和限制加剧对全球经济和贸易的负面影响，这种影响也将更加广泛地显现。

预计血癌发生率的上升将推动血液肿瘤检测市场的成长。血液肿瘤涵盖一组影响血液、骨髓和淋巴系统的血源性癌症，包括白血病、淋巴瘤和骨髓瘤。这些疾病的早期诊断至关重要，而血液肿瘤检测在这方面发挥着至关重要的作用。例如，美国癌症协会预测，到2023年，白血病将影响约59,610名美国，并造成23,710人死亡。此外，非何杰金氏淋巴瘤预计将影响美国80,550人，并导致20,180人死亡。因此，血癌盛行率的上升是推动血液肿瘤检测市场向前发展的关键因素。

预计未来几年，不断增长的医疗保健支出将推动血液肿瘤检测市场的成长。医疗保健支出是指特定时期内，特定地区、国家或经济体分配给医疗保健部门的公共和私人资金总额。将这些资金合理分配给血液肿瘤检测，将有助于提高诊断准确性，实现个人化治疗方法，并改善复杂血液肿瘤领域的患者预后。例如，英国国家统计局2024年5月的报告显示，2022年至2023年，医疗保健总支出名义上增加了5.6%。因此，不断增长的医疗保健支出正在推动血液肿瘤检测市场的成长。

血液肿瘤学检测市场的主要企业正在推出新的创新技术，例如次世代定序仪(NGS)，以提高基因分析的准确性和速度，实现对骨髓恶性肿瘤的全面分析，并支持根据个别患者需求量身定制的个人化治疗策略。 NGS 是一种高通量 DNA 定序技术，可快速且经济高效地分析整个基因组或特定 DNA 区域。例如，2024 年 10 月，专门从事癌症诊断和基因组检测的美国公司 NeoGenomics Inc. 推出了 AML Express，这是一种下一代定序工具，旨在快速检测与急性骨髓性白血病(AML) 相关的突变。这个先进的诊断平台提供高精度和快速的周转时间，帮助肿瘤科医师及时做出有针对性的治疗决策。 AML Express 旨在透过提供与急性骨髓性白血病相关的特定基因图谱的准确突变见解来改善患者预后。

血液肿瘤学检测市场的主要企业正在采取策略联盟的方式，以补充其血液肿瘤学产品组合。策略伙伴关係关係旨在利用彼此的优势和资源，实现通用利益和成功。例如，施维雅实验室 (Servier Laboratories) 与凯杰公司 (QIAGEN NV) 合作开发 mIDH1 伴随诊断检测。该检测旨在透过基于 PCR 的诊断检测快速识别携带 IDH1 基因突变的患者，从而补充施维雅的 AML 治疗方案。总部位于德国的分子诊断公司凯杰公司 (QIAGEN) 将根据一项主合作协议开发和检验该检测。

2023年1月，美国领先的製药公司默克公司（Merck & Co. Inc.）收购了Imago BioSciences, Inc.，后者是一家专注于血液肿瘤检测、诊断以及相关血液疾病治疗的生物技术公司。此次收购符合默克公司致力于透过投资创新解决方案和增强产品线来加强其在血液学领域的影响力的承诺。

血液学和肿瘤学检测市场的主要企业包括 F. Hoffmann-La Roche Ltd.、Abbott Laboratories、Thermo Fisher Scientific Inc.、Illumina Inc.、Invivoscribe Inc.、Qiagen NV、Bio-Rad Laboratories Inc.、Archerdx Inc.、ARUP Laborator Inc.、Bio-Rad Laboratories Inc.、Archerdx Inc.、ARUP Laborator Inc.、Airectm. Inc.、CORE Diagnostics Inc.、Genoptix Inc.、GenPath Diagnostics、NeoGenomics Laboratories Inc.、西门子股份公司、Sysmex Corporation、Laboratory Corporation of America Holdings、安捷伦科技、丹纳赫公司、Grifols SA、Diaorin SpA、HTG Molecular Diagnostics Inc. 和 Adaonos Health. 和 Adaoecular Diaga Health。

2024年，北美是血液肿瘤检测市场最大的地区。预计亚太地区将成为预测期内血液肿瘤检测全球市场报告中成长最快的地区。血液肿瘤检测市场报告涵盖亚太地区、西欧、中欧和东欧、北美、南美以及中东和非洲。

血液学和肿瘤学检测市场报告涵盖的国家：澳洲、巴西、中国、法国、德国、印度、印尼、日本、俄罗斯、韩国、英国、美国、加拿大、义大利、西班牙

血液肿瘤学检测市场由提供采样和诊断服务的营业单位所获得的收益所构成。市场规模包括服务供应商销售的或包含在其服务产品中的相关商品的价值。血液肿瘤学检测市场还包括用于提供血液肿瘤学检测服务的耗材和设备的销售。该市场的价值是指“出厂价”，即商品製造商或生产商销售给其他营业单位（包括下游製造商、批发商、经销商和零售商）或直接销售给最终客户的商品价值。该市场中的商品价值也包括商品製造商销售的相关服务。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球血液学和肿瘤学检测：PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 最终用途产业分析
  • 全球血液学和肿瘤学检测市场：增长率分析
  • 全球血液学和肿瘤学检测市场表现：规模与成长，2019-2024
  • 全球血液学和肿瘤学检测市场预测：规模与成长，2024-2029 年，2034 年
  • 全球血液学和肿瘤学检测：总目标市场（TAM）

第六章 市场细分

  • 全球血液学及肿瘤学检测市场（依产品及服务、绩效及预测），2019-2024 年、2024-2029 年、2034 年
  • 检测套件和试剂
  • 服务
  • 全球血液学和肿瘤学检测市场（按癌症类型、表现和预测），2019-2024 年、2024-2029 年、2034 年
  • 白血病
  • 淋巴瘤
  • 多发性骨髓瘤
  • 其他的
  • 全球血液学和肿瘤学检测市场（按技术、性能和预测），2019-2024 年、2024-2029 年和 2034 年
  • 聚合酵素链锁反应（PCR）
  • 免疫组织化学（IHC）
  • 下一代定序（NGS）
  • 其他的
  • 全球血液学和肿瘤学检测市场（按最终用户、绩效和预测），2019-2024 年、2024-2029 年、2034 年
  • 医院
  • 学术研究机构
  • 其他的
  • 全球血液学和肿瘤学检测市场：检测试剂套件和试剂细分，按类型、性能和预测，2019-2024 年、2024-2029 年、2034 年
  • PCR套件
  • 次世代定序 (NGS)套件
  • 流式细胞技术试剂
  • ELISA套件
  • 抗体
  • 全球血液学和肿瘤学检测市场：服务细分、类型、表现和预测，2019-2024 年、2024-2029 年、2034 年
  • 测试服务
  • 咨询服务
  • 数据分析服务

第七章 区域和国家分析

  • 全球血液学和肿瘤学检测市场：2019-2024 年、2024-2029 年和 2034 年区域表现和预测
  • 全球血液学和肿瘤学检测市场：国家、绩效及预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 血液学和肿瘤学检测市场：竞争格局
  • 血液学和肿瘤学检测市场：公司简介
    • F. Hoffmann-La Roche Ltd.
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Illumina Inc.
    • Invivoscribe Inc.

第31章：其他领先和创新企业

  • Qiagen NV
  • Bio-Rad Laboratories Inc.
  • Archerdx Inc.
  • ARUP Laboratories Inc.
  • Asuragen Inc.
  • Adaptive BIoTechnologies Corp.
  • Cepheid Inc.
  • EntroGen Inc.
  • CORE Diagnostics Inc.
  • Genoptix Inc.
  • GenPath Diagnostics
  • NeoGenomics Laboratories Inc.
  • Siemens AG
  • Sysmex Corporation
  • Laboratory Corporation of America Holdings

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第35章：市场潜力大的国家与策略

  • 2029 年血液学和肿瘤学检测市场：提供新机会的国家
  • 2029 年血液学和肿瘤学检测市场：细分市场将带来新机会
  • 2029 年血液学和肿瘤学检测市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r24190u

Hemato-oncology testing involves diagnostic procedures designed to identify symptoms of blood disorders and blood cancers. These tests play a crucial role in diagnosing conditions such as anemia, infections, hemophilia, blood-clotting disorders, and leukemia.

The primary products and services associated with hemato-oncology testing include assay kits, reagents, and testing services. Assay kits and reagents encompass instruments and chemicals utilized together to analyze specific substances. The testing procedures cover various cancer types, including leukemia, lymphoma, multiple myeloma, and others. The technologies employed for these tests include polymerase chain reaction (PCR), immunohistochemistry (IHC), next-generation sequencing (NGS), and other advanced techniques. The end-users of hemato-oncology testing include hospitals, academic and research institutes, and other healthcare entities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The hemato oncology testing market research report is one of a series of new reports from The Business Research Company that provides hemato oncology testing market statistics, including hemato oncology testing industry global market size, regional shares, competitors with hemato oncology testing market share, detailed hemato oncology testing market segments, market trends, and opportunities, and any further data you may need to thrive in the hemato oncology testing industry. This hemato oncology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The hemato oncology testing market size has grown rapidly in recent years. It will grow from $3.5 billion in 2024 to $3.93 billion in 2025 at a compound annual growth rate (CAGR) of 12.5%. The growth in the historic period can be attributed to increasing cancer incidence, growing awareness and screening programs, rising healthcare expenditure, increasing adoption of personalized medicine, and increasing incidence of blood disorders.

The hemato oncology testing market size is expected to see rapid growth in the next few years. It will grow to $6.76 billion in 2029 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to personalized medicine trends, integration of artificial intelligence, rising geriatric population, advancements in genomic research, and rising demand for early cancer detection. Major trends in the forecast period include technological advancements in genomic testing, liquid biopsy for non-invasive testing, collaborations and partnerships in the industry, regulatory landscape and standardization, and technological advancements.

The forecast of 14.5% growth over the next five years indicates a slight reduction of 0.1% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for flow cytometry antibodies and minimal residual disease assay kits, sourced from key regions such as India and Ireland, which could lead to slower leukemia diagnosis and increased hematopathology laboratory costs.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The anticipated rise in the incidence of hematologic cancer is set to be a driving force behind the growth of the hemato-oncology testing market. Hematologic cancer encompasses a group of cancers originating in the blood, affecting the blood, bone marrow, and lymphatic system, including conditions such as leukemia, lymphoma, and myeloma. Early diagnosis is crucial for these diseases, and hemato-oncology testing plays a pivotal role in achieving this. As an illustration, the American Cancer Society estimates that in 2023, leukemia is expected to impact approximately 59,610 Americans, leading to 23,710 deaths. Additionally, non-Hodgkin lymphoma is projected to affect 80,550 individuals in the United States, resulting in 20,180 deaths. Hence, the increasing prevalence of hematologic cancers is a significant driver propelling the hemato-oncology testing market forward.

The increasing healthcare expenditure is projected to drive the growth of the hemato-oncology testing market in the coming years. Healthcare expenditure refers to the total funds, both public and private, allocated to the healthcare sector within a specific geographical area, country, or economy over a defined period. Proper allocation of these funds towards hemato-oncology testing enhances diagnostic accuracy, enables personalized treatment approaches, and improves patient outcomes in the complex field of hematopoietic tumors. For example, a report from the Office for National Statistics, a UK-based government department, revealed in May 2024 that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to a growth of only 0.9% in 2022. Therefore, the rise in healthcare expenditure is fueling the growth of the hemato-oncology testing market.

Key companies in the hemato-oncology testing market are implementing new innovations such as next-generation sequencing (NGS) to enhance the accuracy and speed of genetic analysis, enable comprehensive profiling of hematologic malignancies, and support personalized treatment strategies tailored to the needs of individual patients. NGS is a high-throughput DNA sequencing technology that facilitates rapid and cost-effective analysis of entire genomes or specific DNA regions. For example, in October 2024, NeoGenomics Inc., a U.S.-based company specializing in cancer diagnostics and genomic testing, launched AML Express, a next-generation sequencing tool designed for the swift detection of mutations related to Acute Myeloid Leukemia (AML). This advanced diagnostic platform provides high accuracy and quick turnaround times, assisting oncologists in making timely and targeted treatment decisions. AML Express aims to enhance patient outcomes by delivering precise mutation insights tailored to the specific genetic profiles associated with AML.

Major companies in the hemato-oncology testing market are adopting a strategic partnership approach to supplement their hemato-oncology portfolio. Strategic partnerships involve leveraging mutual strengths and resources to achieve shared benefits and success. An instance of this is the collaboration between Servier Laboratories and QIAGEN N.V. to develop an mIDH1 companion diagnostic test. This test is intended to complement Servier's AML therapies by swiftly identifying patients with IDH1 gene mutations using a PCR-based diagnostic test. QIAGEN, a Germany-based molecular diagnostics company, will develop and validate this test under the Master Cooperation Agreement.

In January 2023, Merck & Co. Inc., a leading US-based pharmaceutical company, acquired Imago BioSciences, Inc., a biotechnology company focusing on diagnostic and therapeutic products for hemato-oncology testing and related blood disorders. This acquisition aligns with Merck's commitment to fortify its presence in the hematology field by investing in innovative solutions and strengthening its pipeline.

Major companies operating in the hemato oncology testing market include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., Illumina Inc., Invivoscribe Inc., Qiagen N.V., Bio-Rad Laboratories Inc., Archerdx Inc., ARUP Laboratories Inc., Asuragen Inc., Adaptive Biotechnologies Corp., Cepheid Inc., EntroGen Inc., CORE Diagnostics Inc., Genoptix Inc., GenPath Diagnostics, NeoGenomics Laboratories Inc., Siemens AG, Sysmex Corporation, Laboratory Corporation of America Holdings, Agilent Technologies, Danaher Corporation, Grifols SA, Diaorin SpA, HTG Molecular Diagnostics Inc., Admera Health

North America was the largest region in the hemato oncology testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global hemato oncology testing market report during the forecast period. The regions covered in the hemato oncology testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the hemato oncology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The hemato oncology testing market consists of revenues earned by entities by providing sampling and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemato-oncology testing market also includes the sales of consumables and instruments which are used to provide hemato-oncology testing services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hemato Oncology Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on hemato oncology testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hemato oncology testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hemato oncology testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product And Services: Assay Kits And Reagents; Services
  • 2) By Cancer Type: Leukemia; Lymphoma; Multiple Myeloma; Other Cancers
  • 3) By Technology: Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); Next-Generation Sequencing (NGS); Other Technologies
  • 4) By End User: Hospitals; Academic And Research Institutes; Other End Users
  • Subsegments:
  • 1) By Assay Kits And Reagents: PCR Kits; Next-Generation Sequencing (NGS) Kits; Flow Cytometry Reagents; ELISA Kits; Antibodies
  • 2) By Services: Testing Services; Consultation Services; Data Analysis Services
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Thermo Fisher Scientific Inc.; Illumina Inc.; Invivoscribe Inc.; Qiagen N.V.; Bio-Rad Laboratories Inc.; Archerdx Inc.; ARUP Laboratories Inc.; Asuragen Inc.; Adaptive Biotechnologies Corp.; Cepheid Inc.; EntroGen Inc.; CORE Diagnostics Inc.; Genoptix Inc.; GenPath Diagnostics; NeoGenomics Laboratories Inc.; Siemens AG; Sysmex Corporation; Laboratory Corporation of America Holdings; Agilent Technologies; Danaher Corporation; Grifols SA; Diaorin SpA; HTG Molecular Diagnostics Inc.; Admera Health
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Hemato Oncology Testing Market Characteristics

3. Hemato Oncology Testing Market Trends And Strategies

4. Hemato Oncology Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Hemato Oncology Testing Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Hemato Oncology Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Hemato Oncology Testing Market Growth Rate Analysis
  • 5.4. Global Hemato Oncology Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Hemato Oncology Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Hemato Oncology Testing Total Addressable Market (TAM)

6. Hemato Oncology Testing Market Segmentation

  • 6.1. Global Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Assay Kits And Reagents
  • Services
  • 6.2. Global Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Leukemia
  • Lymphoma
  • Multiple Myeloma
  • Other Cancers
  • 6.3. Global Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • Next-Generation Sequencing (NGS)
  • Other Technologies
  • 6.4. Global Hemato Oncology Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Academic And Research Institutes
  • Other End Users
  • 6.5. Global Hemato Oncology Testing Market, Sub-Segmentation Of Assay Kits And Reagents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • PCR Kits
  • Next-Generation Sequencing (NGS) Kits
  • Flow Cytometry Reagents
  • ELISA Kits
  • Antibodies
  • 6.6. Global Hemato Oncology Testing Market, Sub-Segmentation Of Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Testing Services
  • Consultation Services
  • Data Analysis Services

7. Hemato Oncology Testing Market Regional And Country Analysis

  • 7.1. Global Hemato Oncology Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Hemato Oncology Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Hemato Oncology Testing Market

  • 8.1. Asia-Pacific Hemato Oncology Testing Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Hemato Oncology Testing Market

  • 9.1. China Hemato Oncology Testing Market Overview
  • 9.2. China Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Hemato Oncology Testing Market

  • 10.1. India Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Hemato Oncology Testing Market

  • 11.1. Japan Hemato Oncology Testing Market Overview
  • 11.2. Japan Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Hemato Oncology Testing Market

  • 12.1. Australia Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Hemato Oncology Testing Market

  • 13.1. Indonesia Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Hemato Oncology Testing Market

  • 14.1. South Korea Hemato Oncology Testing Market Overview
  • 14.2. South Korea Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Hemato Oncology Testing Market

  • 15.1. Western Europe Hemato Oncology Testing Market Overview
  • 15.2. Western Europe Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Hemato Oncology Testing Market

  • 16.1. UK Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Hemato Oncology Testing Market

  • 17.1. Germany Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Hemato Oncology Testing Market

  • 18.1. France Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Hemato Oncology Testing Market

  • 19.1. Italy Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Hemato Oncology Testing Market

  • 20.1. Spain Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Hemato Oncology Testing Market

  • 21.1. Eastern Europe Hemato Oncology Testing Market Overview
  • 21.2. Eastern Europe Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Hemato Oncology Testing Market

  • 22.1. Russia Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Hemato Oncology Testing Market

  • 23.1. North America Hemato Oncology Testing Market Overview
  • 23.2. North America Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Hemato Oncology Testing Market

  • 24.1. USA Hemato Oncology Testing Market Overview
  • 24.2. USA Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Hemato Oncology Testing Market

  • 25.1. Canada Hemato Oncology Testing Market Overview
  • 25.2. Canada Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Hemato Oncology Testing Market

  • 26.1. South America Hemato Oncology Testing Market Overview
  • 26.2. South America Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Hemato Oncology Testing Market

  • 27.1. Brazil Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Hemato Oncology Testing Market

  • 28.1. Middle East Hemato Oncology Testing Market Overview
  • 28.2. Middle East Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Hemato Oncology Testing Market

  • 29.1. Africa Hemato Oncology Testing Market Overview
  • 29.2. Africa Hemato Oncology Testing Market, Segmentation By Product And Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Hemato Oncology Testing Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Hemato Oncology Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Hemato Oncology Testing Market Competitive Landscape And Company Profiles

  • 30.1. Hemato Oncology Testing Market Competitive Landscape
  • 30.2. Hemato Oncology Testing Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Invivoscribe Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Hemato Oncology Testing Market Other Major And Innovative Companies

  • 31.1. Qiagen N.V.
  • 31.2. Bio-Rad Laboratories Inc.
  • 31.3. Archerdx Inc.
  • 31.4. ARUP Laboratories Inc.
  • 31.5. Asuragen Inc.
  • 31.6. Adaptive Biotechnologies Corp.
  • 31.7. Cepheid Inc.
  • 31.8. EntroGen Inc.
  • 31.9. CORE Diagnostics Inc.
  • 31.10. Genoptix Inc.
  • 31.11. GenPath Diagnostics
  • 31.12. NeoGenomics Laboratories Inc.
  • 31.13. Siemens AG
  • 31.14. Sysmex Corporation
  • 31.15. Laboratory Corporation of America Holdings

32. Global Hemato Oncology Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Hemato Oncology Testing Market

34. Recent Developments In The Hemato Oncology Testing Market

35. Hemato Oncology Testing Market High Potential Countries, Segments and Strategies

  • 35.1 Hemato Oncology Testing Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Hemato Oncology Testing Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Hemato Oncology Testing Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer